Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications.
Guarnotta, V., Ciresi, A., Pizzolanti, G., Giordano, C. (2017). Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease. In Abstract Book SIE 2017 (pp.190-190).
Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease
GUARNOTTA, Valentina;CIRESI, Alessandro;PIZZOLANTI, Giuseppe;GIORDANO, Carla
2017-01-01
Abstract
Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications.File | Dimensione | Formato | |
---|---|---|---|
Guarnotta - pasireotide.pdf
accesso aperto
Descrizione: abstract
Dimensione
765.09 kB
Formato
Adobe PDF
|
765.09 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.